Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

MLA

Volkmann, Elizabeth R., et al. “Short-Term Progression of Interstitial Lung Disease in Systemic Sclerosis Predicts Long-Term Survival in Two Independent Clinical Trial Cohorts.” Annals of the Rheumatic Diseases, vol. 78, no. 1, Jan. 2019, pp. 122–30. EBSCOhost, https://doi.org/10.1136/annrheumdis-2018-213708.

APA

Volkmann, E. R., Tashkin, D. P., Sim, M., Li, N., Goldmuntz, E., Keyes-Elstein, L., Pinckney, A., Furst, D. E., Clements, P. J., Khanna, D., Steen, V., Schraufnagel, D. E., Arami, S., Hsu, V., Roth, M. D., Elashoff, R. M., & Sullivan, K. M. (2019). Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases, 78(1), 122–130. https://doi.org/10.1136/annrheumdis-2018-213708

Chicago

Volkmann, Elizabeth R, Donald P Tashkin, Myung Sim, Ning Li, Ellen Goldmuntz, Lynette Keyes-Elstein, Ashley Pinckney, et al. 2019. “Short-Term Progression of Interstitial Lung Disease in Systemic Sclerosis Predicts Long-Term Survival in Two Independent Clinical Trial Cohorts.” Annals of the Rheumatic Diseases 78 (1): 122–30. doi:10.1136/annrheumdis-2018-213708.